Jefferies has moved CSL Limited down one rating notch to "hold" from "buy" and lowered its target price to A$108 from A$195, a cut of 45%. The brokerage pointed to a series of compounding pressures across both CSL Vifor and CSL Behring divisions and said its fiscal year 2027 net profit after tax estimate sits about 10% below FactSet consensus.
At the time of the note CSL shares were trading at A$99.26. Jefferies reported the stock's 52-week trading range as A$93.64 to A$275.79, and calculated a market capitalisation of A$48.3 billion.
The revised A$108 target is based on an equal blend of two valuation approaches tied to fiscal year 2027 metrics: a price-to-earnings multiple of 11.5 times, which translates to US$75.92 per share, and an EV/EBITDA multiple of 8.5 times, which translates to US$79.54 per share. Jefferies said this blended valuation used an exchange rate of A$/US$ 0.72.
On the company outlook, Jefferies trimmed its fiscal year 2027 revenue forecast to US$15.46 billion from a prior US$15.73 billion and lowered its FY27 adjusted earnings per share projection to US$5.97 from US$6.11, a 2.3% reduction. Fiscal year 2028 EPS was also revised down to US$6.26 from US$6.40, a 2.1% cut.
For CSL Vifor, which Jefferies said represented roughly 15% of estimated group revenue for fiscal year 2026, the note enumerated several headwinds. The brokerage cited generic entrants, insurer step-edit protocols in the U.S., and the removal of Velphoro from the higher-priced TDAPA reimbursement program as key drags on the business.
Jefferies noted that the U.S. Food and Drug Administration approved two generic iron sucrose injections in August 2025, and that these approvals had pushed pricing sharply lower from the first half of calendar year 2026. The firm modelled a 15% decline in fiscal year 2027 iron revenue within CSL Vifor and anticipated a 300 basis point contraction in the Vifor EBIT margin, which had been estimated at 48.1% in fiscal year 2026.
On insurer step edits, Jefferies pointed to a stark price differential based on U.S. Centers for Medicare and Medicaid Services pricing for a full treatment course: Injectafer at US$1,586 versus Venofer at US$194, or roughly 8.2 times more expensive for Injectafer, the brokerage said. Separately, Jefferies highlighted that Velphoro, which accounted for 2% of estimated fiscal year 2026 group revenue, is slated to move into the standard CMS dialysis payment bundle at the end of calendar year 2026. Jefferies modelled a 50% revenue decline for Velphoro in fiscal year 2027 as a result.
Jefferies also flagged U.S. regulatory risk around the drug Tavneos after the Center for Drug Evaluation and Research proposed withdrawing the medicine from the U.S. market. While CSL Vifor holds commercialisation rights for Tavneos outside the United States, the drug generated US$112 million in fiscal year 2025, equal to about 0.7% of CSL Group revenue, and Jefferies assumed a 50% decline in Tavneos revenue in fiscal year 2027.
Turning to CSL Behring, which Jefferies said contributed about 69% of estimated group revenue in fiscal year 2026, the broker observed that U.S. immunoglobulin spot price growth was running below historical norms and interpreted that as evidence of above-average end-user inventory. The note also referenced developments in China where albumin volumes had stabilised but market value had declined; CSL itself had signalled an expected revenue impact of roughly US$200 million from that dynamic.
Jefferies further noted that CSL had cited a US$300 million revenue impact tied to normalisation of U.S. immunoglobulin channel inventory. The brokerage emphasised these revenue pressures while observing broader valuation metrics: CSL's 12-month forward price-to-earnings multiple was 11.0 times, which Jefferies said is about 66% below the stock's historical mean of 32.4 times based on the firm's estimates and IRESS data.
The combination of lower revenue and earnings assumptions, product-level reimbursement shifts, generic competition, regulatory uncertainty, and channel inventory normalisation underpinned Jefferies' decision to downgrade the stock and materially reduce the target price.
Summary
Jefferies downgraded CSL to a "hold" rating and cut its price target to A$108 from A$195 after lowering FY27 and FY28 revenue and EPS forecasts. The broker pointed to pressures at both CSL Vifor and CSL Behring, including generic competition, insurer step-edit protocols, the removal of Velphoro from a higher-priced reimbursement program, regulatory scrutiny of Tavneos in the U.S., softer immunoglobulin pricing, and channel inventory normalisation.
Key points
- Jefferies cut CSL's target price to A$108 (from A$195) and downgraded the rating to "hold"; its FY27 NPAT estimate is around 10% below FactSet consensus.
- CSL Vifor faces multiple near-term headwinds: generic iron sucrose approvals, insurer step-edit protocols, and Velphoro's reimbursement shift; Jefferies models a 15% decline in FY27 Vifor iron revenue and a 300 bp margin contraction.
- CSL Behring's revenue is affected by softer U.S. immunoglobulin spot-price growth, albumin value declines in China (about US$200 million impact), and a US$300 million impact from U.S. IG channel inventory normalisation.
Risks and uncertainties
- Regulatory risk: the U.S. CDER's proposed withdrawal of Tavneos creates uncertainty for product revenue, which Jefferies models as a 50% decline in FY27.
- Reimbursement and pricing changes: movement of Velphoro into the standard CMS dialysis payment bundle and generic approvals for iron sucrose threaten revenue and margins in CSL Vifor.
- Inventory and pricing dynamics: below-average immunoglobulin spot-price growth and above-average end-user inventory in the U.S., plus albumin value declines in China, create revenue volatility for CSL Behring.
Market metrics and valuation
Jefferies' adjusted multiples and revised forecasts produce an A$108 target derived equally from P/E and EV/EBITDA approaches on fiscal year 2027 estimates, using an A$/US$ exchange rate of 0.72. The broker now forecasts FY27 revenue of US$15.46 billion and adjusted EPS of US$5.97; FY28 EPS is modelled at US$6.26. Jefferies also highlighted that CSL's 12-month forward P/E is 11.0 times, about 66% below its historical mean of 32.4 times based on Jefferies' estimates and IRESS data.